by admin | Jun 4, 2020 | 2020, Post-Pipeline
2A Pharma’s anti-amyloid-beta vaccine candidate, AAVLP-Amyloid-β, has in laboratory tests with transgenic mice overexpressing amyloid-beta mutant protein been shown to eliminate amyloid-beta soluble protein, clear plaque from the cortex and significantly reduce plaque...
by admin | Mar 25, 2019 | 2019, Media
Article about 2A Pharma in the Danish pharma/biotech media MedWatch (behind paywall): Danish English: https://medwatch.dk/secure/Top_picks_in_english/article11274345.ece
by admin | Dec 14, 2018 | 2018, HPV, Milestones
2A Pharma has received approval from the UK Medicines and Healthcare products Regulatory Authority and from the local Ethics Committee to proceed with a first-in-human study of 2AP01, which is being developed as broad coverage prophylactic HPV vaccine formulated...
by admin | Sep 27, 2018 | 2018, Collaboration, Funding & Investments, Head & Neck Cancer, Milestones
We are extremely pleased to announce that 2A Pharma in collaboration with partners from The Danish Technological Institute and Danish biotech company DNA Sense have been granted EUR 653,000 Eurostars funding for 2AP07, a project to develop a therapeutic head...
by admin | Aug 31, 2018 | 2018, Events
2A Pharma is very happy to announce that we will present at BIO Europe 2018. Please join us on Tuesday, 6 November 2018 at 4.30pm in room B3 (level 0).
Recent Comments